Tonix Pharmaceuticals (TNXP) Projected to Post Quarterly Earnings on Monday

Tonix Pharmaceuticals (NASDAQ:TNXP) will likely be releasing its earnings data before the market opens on Monday, April 7th. Analysts expect Tonix Pharmaceuticals to post earnings of ($6.23) per share and revenue of $3.35 million for the quarter.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($9.77) EPS for the quarter, missing the consensus estimate of ($6.23) by ($3.54). Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The business had revenue of $2.58 million for the quarter, compared to the consensus estimate of $3.20 million. On average, analysts expect Tonix Pharmaceuticals to post $-1,763 EPS for the current fiscal year and $-542 EPS for the next fiscal year.

Tonix Pharmaceuticals Stock Performance

Tonix Pharmaceuticals stock opened at $20.17 on Monday. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. Tonix Pharmaceuticals has a twelve month low of $6.76 and a twelve month high of $672.00. The company’s 50-day moving average price is $18.79 and its 200-day moving average price is $20.20. The company has a market cap of $37.70 million, a PE ratio of 0.00 and a beta of 2.23.

Analysts Set New Price Targets

TNXP has been the topic of a number of recent research reports. StockNews.com began coverage on Tonix Pharmaceuticals in a research report on Monday, February 10th. They set a “sell” rating on the stock. Noble Financial restated an “outperform” rating and set a $70.00 price target on shares of Tonix Pharmaceuticals in a report on Thursday, March 20th.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.